טוען...
Basal Insulin Use With GLP-1 Receptor Agonists
IN BRIEF The combination of basal insulin and a glucagon-like peptide 1 receptor agonist is becoming increasingly common and offers several potential benefits to patients with type 2 diabetes. Clinical studies have demonstrated improved glycemic control and low risks of hypoglycemia and weight gain...
שמור ב:
| הוצא לאור ב: | Diabetes Spectr |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Diabetes Association
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5001217/ https://ncbi.nlm.nih.gov/pubmed/27574369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/diaspect.29.3.152 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|